Related references
Note: Only part of the references are listed.The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis
Maria Olsen et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Role of trypsin and protease-activated receptor-2 in ovarian cancer
Kyu Kwang Kim et al.
PLOS ONE (2020)
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Katharine K. Brieger et al.
GYNECOLOGIC ONCOLOGY (2020)
Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis
Jinping Li et al.
CLINICA CHIMICA ACTA (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Usha Menon et al.
BRITISH JOURNAL OF CANCER (2017)
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study
Mani Nassir et al.
TUMOR BIOLOGY (2016)
HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer
Mona Aarenstrup Karlsen et al.
APMIS (2016)
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis
E. M. J. Meys et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinical, ultrasound parameters and tumor marker-based mathematical models and scoring systems in pre-surgical diagnosis of adnexal tumors
Nabil Abdalla et al.
Ginekologia Polska (2016)
Comparison of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 as Markers in Endometrial Cancer A Meta-Analysis
Lingli Hu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer
Karina Dahl Steffensen et al.
ONCOLOGY LETTERS (2016)
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
Aurelie Pelissier et al.
JOURNAL OF OVARIAN RESEARCH (2016)
Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis
Jeroen Kaijser et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis
Jiwen Wang et al.
TUMOR BIOLOGY (2014)
Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer
Tuulia Vallius et al.
TUMOR BIOLOGY (2014)
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer
Anita Monika Chudecka-Glaz et al.
JOURNAL OF OVARIAN RESEARCH (2014)
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
Elham O. Hamed et al.
DIAGNOSTIC PATHOLOGY (2013)
Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?
Roberto Angioli et al.
GYNECOLOGIC ONCOLOGY (2013)
Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review
Simona Ferraro et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer
Lucia Manganaro et al.
ONCOLOGY REPORTS (2013)
Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer
Sun-Young Kong et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125
Michel Schummer et al.
GYNECOLOGIC ONCOLOGY (2012)
Human epididymis protein 4 (HE4) and ovarian cancer prognosis
Dominique Trudel et al.
GYNECOLOGIC ONCOLOGY (2012)
The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients
Karina Dahl Steffensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Human Epididymis Protein-4 (HE-4): A Novel Cross-Class Protease Inhibitor
Nirmal Chhikara et al.
PLOS ONE (2012)
Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Francesco Plotti et al.
TUMOR BIOLOGY (2012)
High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
Grigorios Kalapotharakos et al.
JOURNAL OF OVARIAN RESEARCH (2012)
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations
Ritu Salani et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2011)
Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management
Elisabetta Bandiera et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases
Yongjung Park et al.
CLINICAL BIOCHEMISTRY (2011)
Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer
Jiheum Paek et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2011)
2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference
Gavin C. E. Stuart et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass
Richard G. Moore et al.
OBSTETRICS AND GYNECOLOGY (2011)
Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment
Neeraj Lalwani et al.
RADIOGRAPHICS (2011)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Ovarian Cancer Pathogenesis: A Model in Evolution
Alison M. Karst et al.
JOURNAL OF ONCOLOGY (2010)
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
K. Huhtinen et al.
BRITISH JOURNAL OF CANCER (2009)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer? A Retrospective Italian Multicentric Study
Angiolo Gadducci et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Comprehensive analysis of HE4 expression in normal and malignant human tissues
Mary T. Galgano et al.
MODERN PATHOLOGY (2006)
Systemic therapy for ovarian cancer: Current status and new treatments
Robert F. Ozols
SEMINARS IN ONCOLOGY (2006)
Tumour-cell invasion and migration: Diversity and escape mechanisms
P Friedl et al.
NATURE REVIEWS CANCER (2003)
Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group
D Timmerman et al.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2000)
Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines
ML Larramendy et al.
CANCER GENETICS AND CYTOGENETICS (2000)